vs
百利高（PRGO）与罗克韦尔自动化（ROK）财务数据对比。点击上方公司名可切换其他公司
罗克韦尔自动化的季度营收约是百利高的1.9倍（$2.1B vs $1.1B），罗克韦尔自动化净利率更高（14.5% vs -127.8%，领先142.3%），罗克韦尔自动化同比增速更快（11.9% vs -2.5%），罗克韦尔自动化自由现金流更多（$170.0M vs $148.6M），过去两年百利高的营收复合增速更高（1.3% vs -0.5%）
百利高（Perrigo）是一家注册于爱尔兰的非处方仿制药生产商，主打自有品牌OTC药品业务。公司70%的净销售额来自美国医疗市场，为优化税务布局将法定总部设在爱尔兰，该地区销售额仅占总营收的0.6%，2013年曾完成美国历史上第六大企业税收倒置交易。
罗克韦尔自动化是总部位于美国威斯康星州密尔沃基的工业自动化及数字化转型技术提供商，旗下拥有Allen-Bradley、FactoryTalk软件、LifecycleIQ服务等核心品牌，全球员工约2.7万人，服务覆盖100多个国家和地区的客户。
PRGO vs ROK — 直观对比
营收规模更大
ROK
是对方的1.9倍
$1.1B
营收增速更快
ROK
高出14.4%
-2.5%
净利率更高
ROK
高出142.3%
-127.8%
自由现金流更多
ROK
多$21.4M
$148.6M
两年增速更快
PRGO
近两年复合增速
-0.5%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $1.1B | $2.1B |
| 净利润 | $-1.4B | $305.0M |
| 毛利率 | 32.6% | 48.3% |
| 营业利润率 | -116.0% | 20.7% |
| 净利率 | -127.8% | 14.5% |
| 营收同比 | -2.5% | 11.9% |
| 净利润同比 | -3093.9% | 65.8% |
| 每股收益（稀释后） | $-10.23 | $2.69 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PRGOROK
| Q4 25 | $1.1B | $2.1B | ||
| Q3 25 | $1.0B | $2.3B | ||
| Q2 25 | $1.1B | $2.1B | ||
| Q1 25 | $1.0B | $2.0B | ||
| Q4 24 | $1.1B | $1.9B | ||
| Q3 24 | $1.1B | $2.0B | ||
| Q2 24 | $1.1B | $2.1B | ||
| Q1 24 | $1.1B | $2.1B |
净利润PRGOROK
| Q4 25 | $-1.4B | $305.0M | ||
| Q3 25 | $7.5M | $138.0M | ||
| Q2 25 | $-8.4M | $295.0M | ||
| Q1 25 | $-6.4M | $252.0M | ||
| Q4 24 | $-44.4M | $184.0M | ||
| Q3 24 | $-21.0M | $239.1M | ||
| Q2 24 | $-108.4M | $232.0M | ||
| Q1 24 | $2.0M | $266.2M |
毛利率PRGOROK
| Q4 25 | 32.6% | 48.3% | ||
| Q3 25 | 36.1% | 69.4% | ||
| Q2 25 | 34.4% | 40.9% | ||
| Q1 25 | 37.6% | 40.5% | ||
| Q4 24 | 33.9% | 38.4% | ||
| Q3 24 | 37.2% | 37.9% | ||
| Q2 24 | 37.0% | 38.8% | ||
| Q1 24 | 33.1% | 39.2% |
营业利润率PRGOROK
| Q4 25 | -116.0% | 20.7% | ||
| Q3 25 | 7.0% | 2.7% | ||
| Q2 25 | 4.3% | 16.0% | ||
| Q1 25 | 4.5% | 14.9% | ||
| Q4 24 | 10.0% | 17.1% | ||
| Q3 24 | 7.4% | 13.5% | ||
| Q2 24 | -2.5% | 12.4% | ||
| Q1 24 | -5.1% | 14.6% |
净利率PRGOROK
| Q4 25 | -127.8% | 14.5% | ||
| Q3 25 | 0.7% | 6.0% | ||
| Q2 25 | -0.8% | 13.8% | ||
| Q1 25 | -0.6% | 12.6% | ||
| Q4 24 | -3.9% | 9.8% | ||
| Q3 24 | -1.9% | 11.7% | ||
| Q2 24 | -10.2% | 11.3% | ||
| Q1 24 | 0.2% | 12.5% |
每股收益（稀释后）PRGOROK
| Q4 25 | $-10.23 | $2.69 | ||
| Q3 25 | $0.05 | $1.24 | ||
| Q2 25 | $-0.06 | $2.60 | ||
| Q1 25 | $-0.05 | $2.22 | ||
| Q4 24 | $-0.32 | $1.61 | ||
| Q3 24 | $-0.15 | $2.09 | ||
| Q2 24 | $-0.79 | $2.02 | ||
| Q1 24 | $0.01 | $2.31 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $444.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.9B | $3.7B |
| 总资产 | $8.5B | $11.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资PRGOROK
| Q4 25 | — | $444.0M | ||
| Q3 25 | $432.1M | $468.0M | ||
| Q2 25 | $454.2M | $495.0M | ||
| Q1 25 | $409.9M | $456.0M | ||
| Q4 24 | $558.8M | $477.0M | ||
| Q3 24 | $1.5B | $471.3M | ||
| Q2 24 | $542.8M | $407.0M | ||
| Q1 24 | $658.5M | $470.5M |
总债务PRGOROK
| Q4 25 | — | — | ||
| Q3 25 | — | $2.6B | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $2.6B | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益PRGOROK
| Q4 25 | $2.9B | $3.7B | ||
| Q3 25 | $4.4B | $3.7B | ||
| Q2 25 | $4.5B | $3.5B | ||
| Q1 25 | $4.4B | $3.4B | ||
| Q4 24 | $4.3B | $3.4B | ||
| Q3 24 | $4.6B | $3.5B | ||
| Q2 24 | $4.5B | $3.3B | ||
| Q1 24 | $4.7B | $3.5B |
总资产PRGOROK
| Q4 25 | $8.5B | $11.2B | ||
| Q3 25 | $10.1B | $11.2B | ||
| Q2 25 | $10.1B | $11.2B | ||
| Q1 25 | $9.8B | $11.0B | ||
| Q4 24 | $9.6B | $10.9B | ||
| Q3 24 | $11.2B | $11.2B | ||
| Q2 24 | $10.4B | $11.2B | ||
| Q1 24 | $10.6B | $11.4B |
负债/权益比PRGOROK
| Q4 25 | — | — | ||
| Q3 25 | — | 0.72× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.73× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $175.4M | $234.0M |
| 自由现金流经营现金流 - 资本支出 | $148.6M | $170.0M |
| 自由现金流率自由现金流/营收 | 13.4% | 8.1% |
| 资本支出强度资本支出/营收 | 2.4% | 3.0% |
| 现金转化率经营现金流/净利润 | — | 0.77× |
| 过去12个月自由现金流最近4个季度 | $145.1M | — |
8季度趋势，按日历期对齐
经营现金流PRGOROK
| Q4 25 | $175.4M | $234.0M | ||
| Q3 25 | $51.7M | $454.0M | ||
| Q2 25 | $75.9M | $527.0M | ||
| Q1 25 | $-64.5M | $199.0M | ||
| Q4 24 | $312.6M | $364.0M | ||
| Q3 24 | $42.2M | $432.3M | ||
| Q2 24 | $9.5M | $279.1M | ||
| Q1 24 | $-1.4M | $119.8M |
自由现金流PRGOROK
| Q4 25 | $148.6M | $170.0M | ||
| Q3 25 | $29.8M | — | ||
| Q2 25 | $56.7M | $489.0M | ||
| Q1 25 | $-90.0M | $171.0M | ||
| Q4 24 | $274.9M | $293.0M | ||
| Q3 24 | $15.1M | — | ||
| Q2 24 | $-18.9M | $238.4M | ||
| Q1 24 | $-26.5M | $68.6M |
自由现金流率PRGOROK
| Q4 25 | 13.4% | 8.1% | ||
| Q3 25 | 2.9% | — | ||
| Q2 25 | 5.4% | 22.8% | ||
| Q1 25 | -8.6% | 8.5% | ||
| Q4 24 | 24.2% | 15.6% | ||
| Q3 24 | 1.4% | — | ||
| Q2 24 | -1.8% | 11.6% | ||
| Q1 24 | -2.4% | 3.2% |
资本支出强度PRGOROK
| Q4 25 | 2.4% | 3.0% | ||
| Q3 25 | 2.1% | — | ||
| Q2 25 | 1.8% | 1.8% | ||
| Q1 25 | 2.4% | 1.4% | ||
| Q4 24 | 3.3% | 3.8% | ||
| Q3 24 | 2.5% | — | ||
| Q2 24 | 2.7% | 2.0% | ||
| Q1 24 | 2.3% | 2.4% |
现金转化率PRGOROK
| Q4 25 | — | 0.77× | ||
| Q3 25 | 6.89× | 3.29× | ||
| Q2 25 | — | 1.79× | ||
| Q1 25 | — | 0.79× | ||
| Q4 24 | — | 1.98× | ||
| Q3 24 | — | 1.81× | ||
| Q2 24 | — | 1.20× | ||
| Q1 24 | -0.70× | 0.45× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PRGO
| Consumer Self Care Americas | $697.0M | 63% |
| Digestive Health | $123.9M | 11% |
| Nutrition | $108.3M | 10% |
| Healthy Lifestyle | $94.8M | 9% |
| Pain And Sleep Aids | $87.1M | 8% |
ROK
| Productsand Solutions | $1.9B | 89% |
| Lifecycle Services Segment | $259.0M | 12% |
